Insulet Corporation (PODD)
After hours:
Chart Events
Performance Outlook
| Previous Close | 199.06 |
| Open | 198.98 |
| Bid | 168.20 x 900 |
| Ask | 290.00 x 800 |
| Day's Range | 195.59 - 206.23 |
| 52 Week Range | 181.00 - 324.81 |
| Volume | |
| Avg. Volume | 585,546 |
| Market Cap | 13.58B |
| Beta (5Y Monthly) | 0.70 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.44 |
| Earnings Date | Feb 21, 2022 - Feb 25, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 318.60 |
- GlobeNewswire
AeroClean Announces Appointment of Timothy J. Scannell to Board of Directors
PALM BEACH GARDENS, Fla., May 12, 2022 (GLOBE NEWSWIRE) -- AeroClean Technologies (“AeroClean” or the “Company”) (Nasdaq: AERC), a pathogen elimination technology company harnessing patented UV-C LED technology with Pūrgo™ to significantly reduce and remove harmful pathogens to keep work, play and life going, today announced the appointment of Timothy J. Scannell, former President and Chief Operating Officer at Stryker, to its Board of Directors (the “Board”). On May 11, 2022, the Board appointe
- Zacks
Insulet (PODD) Q1 Earnings Surpass Estimates, Margins Grow
Robust adoption of Omnipod DASH and record new customer starts have contributed to Insulet's (PODD) Q1 performance.
- Benzinga
Insulet Q1 Earnings Beats Street View, Says Omnipod 5 Rollout Is 'Progressing Very Well'
View more earnings on PODDSee more from BenzingaInsulet Highlights New Data For Omnipod 5 System For Type 1, Type 2 DiabetesDon't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
